Lonvoguran Ziclumeran

N/A

Report date: 2026/04/30 14:22:20

Base Information

Drug NameLonvoguran Ziclumeran
Drug Alias Namelonvo-zNTLA-2002
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > LNP
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A